Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions
- Acronyms FYC01S
- Sponsors Eisai Co Ltd
- 01 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2019 Planned End Date changed from 27 Feb 2020 to 28 Feb 2021.
- 01 Mar 2019 Planned primary completion date changed from 27 Feb 2020 to 28 Feb 2021.